Compare WVE & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | EVC |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.8M | 683.9M |
| IPO Year | 2015 | 2000 |
| Metric | WVE | EVC |
|---|---|---|
| Price | $3.45 | $6.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $18.06 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 2.95% |
| EPS Growth | N/A | ★ 47.59 |
| EPS | N/A | ★ 0.32 |
| Revenue | $3,704,000.00 | ★ $536,034,000.00 |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.25 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $3.43 | $1.95 |
| 52 Week High | $21.73 | $13.74 |
| Indicator | WVE | EVC |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 25.65 |
| Support Level | N/A | $2.89 |
| Resistance Level | $6.33 | $10.09 |
| Average True Range (ATR) | 0.23 | 0.31 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 8.56 | 16.05 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.